Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Frontotemporal Lobar Degeneration Clear all

Conditions: Healthy, Frontotemporal Dementia
Interventions: AL001, Placebo; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Primary Progressive Aphasia, Frontotemporal Dementia
Interventions: Monthly Check-in Session; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Progressive Aphasia
Interventions: Communication Bridge™, Evidence-Based Impairment Focused; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions: Not listed
Lead sponsor: Bastyr University; Other
Eligibility: 19 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions: Intravenous and Intranasal BMSC; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Primary Progressive Aphasia, PPA
Interventions: Active tDCS plus Speech-Language Therapy, Sham tDCS plus Speech-Language Therapy; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment, Aging
Interventions: 18F-MK-6240; Drug
Lead sponsor: Yaakov Stern; Other
Eligibility: 55 Years to 90 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant, Frontotemporal Dementia
Interventions: Vortioxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 708 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2031
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 10 more

Conditions: Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia, Paget Disease of Bone, Frontotemporal Dementia, Myopathy
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Irvine, California

Conditions: Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions: Building Better Caregivers Workshop, Attention Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions: Flortaucipir, Florbetaben, Fluorodeoxyglucose; Drug
Lead sponsor: Indiana University; Other
Eligibility: 40 Years to 64 Years
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions: Biological Sample Collection; Other
Lead sponsor: New York Stem Cell Foundation Research Institute; Other
Eligibility: 30 Days and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2045
U.S. locations: 1
States / cities: New York, New York

Conditions: Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions: Behavioral nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Frontotemporal Dementia
Interventions: Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions: Palliative Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 105 Years
Enrollment: 783 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Semantic Dementia
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Frontotemporal Dementia
Interventions: LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone; Biological · Drug
Lead sponsor: Prevail Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more

Conditions: Alzheimer's Disease
Interventions: 11C-PIB PET Scan, FDG-PET Scan; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 30 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alzheimer Disease
Interventions: 18F-MK-6240, 18F-Florbetaben; Drug
Lead sponsor: Adam Brickman; Other
Eligibility: 35 Years to 85 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild, Dementia Moderate, Dementia Severe, Caregiver Burnout, Caregiver Stress Syndrome
Interventions: Video Intervention Arm; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease, Frontotemporal Dementia, Dementia
Interventions: [18F]RP-115 PET/MRI or PET/CT and MRI; Drug
Lead sponsor: David Wilson; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Interventions: Metformin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Communication Bridge Speech Therapy Research Study

Communication Bridge 3 Study

Modifiable Variables in Parkinsonism (MVP)

Neurologic Stem Cell Treatment Study

Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)

Rural Dementia Caregiver Project

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NYSCF Scientific Discovery Biobank

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

Revealing Engagement Dynamics Among Semantic Dementia Patients

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD